{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:50:19Z","timestamp":1789581019420,"version":"build-2803163510"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100023368","name":"Eisai Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100023368","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s40268-024-00462-w","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T03:49:42Z","timestamp":1717645782000},"page":"211-226","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety and Efficacy of Lemborexant in Insomnia Patients: Results of a Postmarketing Observational Study of Dayvigo\u00ae Tablets"],"prefix":"10.1007","volume":"24","author":[{"given":"Kazuo","family":"Mishima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"key":"462_CR1","unstructured":"Health and Labour Sciences Research Comprehensive Research Project on Measures for Disabled Persons: Study group on clinical practice guidelines for proper usage and discontinuation of hypnotics, and Working Group for Preparation of Guidelines for Use of Hypnotics by the Japanese Society of Sleep Research. Clinical practice guidelines for proper use and discontinuation of hypnotics\u2014insomnia medical manual with an eye on the exit. 2013 [in Japanese]. https:\/\/jssr.jp\/files\/guideline\/suiminyaku-guideline.pdf."},{"key":"462_CR2","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.sleep.2016.05.013","volume":"25","author":"O Itani","year":"2016","unstructured":"Itani O, Kaneita Y, Munezawa T, Mishima K, Jike M, Nakagome S, et al. Nationwide epidemiological study of insomnia in Japan. Sleep Med. 2016;25:130\u20138.","journal-title":"Sleep Med"},{"issue":"3","key":"462_CR3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40801-021-00244-9","volume":"8","author":"K Inada","year":"2021","unstructured":"Inada K, Enomoto M, Yamato K, Mishima K. Prescribing pattern of hypnotic medications in patients initiating treatment at Hapanese hospitals: a nationwide, retrospective, longitudinal, observational study using a claims database. Drugs Real World Outcomes. 2021;8(3):277\u201388.","journal-title":"Drugs Real World Outcomes."},{"key":"462_CR4","unstructured":"Pharmaceutical and Medical Devices Agency. PMDA alert for proper use of drugs: Dependence associated with Benzodiazepine Receptor Agonists. 2017. https:\/\/www.pmda.go.jp\/files\/000217228.pdf."},{"key":"462_CR5","first-page":"73","volume":"11","author":"M Uchiyama","year":"2017","unstructured":"Uchiyama M. Insomnia treatment with orexin receptor antagonists and expectations for the future (feature article: clinical significance of special issue orexin receptor antagonists and expectations for the future). Jpn J Sleep Med Sleep Med Japan. 2017;11:73\u20139.","journal-title":"Jpn J Sleep Med Sleep Med Japan."},{"issue":"2","key":"462_CR6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1254\/fpj.20093","volume":"156","author":"M Koebisu","year":"2021","unstructured":"Koebisu M, Koyama N, Nishida M, Muramoto K. Preclinical and clinical efficacy of orexin receptor antagonist Lemborexant (Dayvigo\u00ae) on insomnia patients. Folia Pharmacol Jpn. 2021;156(2):114\u20139.","journal-title":"Folia Pharmacol Jpn."},{"issue":"9","key":"462_CR7","doi-asserted-by":"publisher","first-page":"zsaa23","DOI":"10.1093\/sleep\/zsaa123.(9)","volume":"43","author":"M K\u00e4rpp\u00e4","year":"2020","unstructured":"K\u00e4rpp\u00e4 M, Yardley J, Pinner K, Filippov G, Zammit G, Moline M, et al. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2. Sleep. 2020;43(9):zsaa23. https:\/\/doi.org\/10.1093\/sleep\/zsaa123.(9).","journal-title":"Sleep"},{"issue":"12","key":"462_CR8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.18254","volume":"2","author":"R Rosenberg","year":"2019","unstructured":"Rosenberg R, Murphy P, Zammit G, Mayleben D, Kumar D, Dhadda S, et al. Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial. JAMA Netw Open. 2019;2(12): e1918254.","journal-title":"JAMA Netw Open"},{"key":"462_CR9","unstructured":"Eisai Co. Ltd. Dayvigo\u00ae Tablets 2.5 mg. Dayvigo\u00ae Tablets 5 mg. Dayvigo\u00ae Tablets 10 mg [package insert]. Revised: 5\/2022 (5th edition)."},{"key":"462_CR10","unstructured":"Uchiyama M. Guidelines for management and treatment of sleep disorders. Jiho, Inc.; 2019."},{"issue":"4","key":"462_CR11","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/cts.13470","volume":"16","author":"Y Takaesu","year":"2023","unstructured":"Takaesu Y, Suzuki M, Moline M, Pinner K, Inabe K, Nishi Y, et al. Effect of discontinuation of lemborexant following long-term treatment of insomnia disorder: secondary analysis of a randomized clinical trial. Clin Transl Sci. 2023;16(4):581\u201392.","journal-title":"Clin Transl Sci"},{"key":"462_CR12","first-page":"209","volume":"12","author":"Y Asai","year":"2018","unstructured":"Asai Y, Sano H, Miyazaki M, Iwakura M, Maeda Y, Hara M. Suvorexant (Belsomra\u00ae Tablets 10 mg, 15 mg, 20 mg) Drug use-results survey (Final report). Jpn J Sleep Med Sleep Med Japan. 2018;12:209\u201327.","journal-title":"Jpn J Sleep Med Sleep Med Japan."},{"issue":"6","key":"462_CR13","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.5664\/jcsm.9150","volume":"17","author":"M Moline","year":"2021","unstructured":"Moline M, Zammit G, Cheng JY, Perdomo C, Kumar D, Mayleben D. Comparison of the effect of lemborexant with placebo and zolpidem tartrate extended release on sleep architecture in older adults with insomnia disorder. J Clin Sleep Med. 2021;17(6):1167\u201374.","journal-title":"J Clin Sleep Med"},{"issue":"10347","key":"462_CR14","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S0140-6736(22)00878-9","volume":"400","author":"F De Crescenzo","year":"2022","unstructured":"De Crescenzo F, D\u2019Al\u00f2 GL, Ostinelli EG, Ciabattini M, Di Franco V, Watanabe N, et al. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. Lancet. 2022;400(10347):170\u201384.","journal-title":"Lancet"}],"container-title":["Drugs in R&amp;D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-024-00462-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-024-00462-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-024-00462-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T10:27:33Z","timestamp":1723199253000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-024-00462-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["462"],"URL":"https:\/\/doi.org\/10.1007\/s40268-024-00462-w","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"9 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Eisai Co., Ltd, Japan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All participants have consented to the submission of the results of this study to <i>Drugs in R&D<\/i>.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Kazuo Mishima accepted the role of medical expert for this study from Eisai Co., Ltd, and received compensation. Kenichi Fujimoto, Akira Endo, and Mika Ishii are employees of Eisai Co., Ltd, who conducted this study. The entire costs of implementation, analysis, and publication of this study were borne by Eisai Co., Ltd. This study was conducted as a postmarketing observational study at each medical institution that had signed a contract based on the Ministerial Ordinance on Good Postmarketing Study Practice for Drugs (GPSP Ordinance) and research expenses were paid to the institutions in accordance with the contract.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The scientific and ethical appropriateness of the plan was discussed by Eisai Co., Ltd and the plan was implemented as the \u2018Postmarketing Observational Study of Dayvigo Tablets: Survey on the Occurrence of Adverse Drug Reactions in Insomnia Patients\u2019 in accordance with the Ministerial Ordinance on Good Postmarketing Study Practice for Drugs (GPSP Ordinance).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The dataset for this study contains data from sites that do not permit third-party provision; therefore, it has not been made publicly available.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data and\/or code availability"}},{"value":"Conceptualization and design: KM, MI. Data acquisition: KF, AE. Data analysis: KF, AE. Data interpretation: KM, KF, AE, MI. Writing (drafting\/revising): KM, KF, AE, MI. Approval of the final manuscript: KM, KF, AE, MI.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}